Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t

Kyle LaHucik

Senior Reporter

Merck, the third-largest pharma R&D spender in 2021, has enlisted outside help in funding its mid-stage schizophrenia program as the Big Pharma looks to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Roy­al­ty Phar­ma bets Mer­ck­'s schiz­o­phre­nia drug can go where Pfiz­er, Take­da and Lund­beck­'s couldn’t

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?